Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 10 min ago
Peer-reviewedCC BY-NC-NDCancer medicine

Age, Comorbidity Burden and Treatment Outcomes in Mature B-Cell Lymphoproliferative Disorders: A Real-World Study.

  • Kevin Nasrinfar1,2
  • Harrison Wildhaber1
  • Rudolf Rohr1
  • Gaëlle Rhyner Agocs3
  • Urban Novak4
  • Alessandra Curioni-Fontecedro1,3
  • Vérène Dougoud-Chauvin3
4 affiliations
  1. 1Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland.
  2. 2CHUV Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  3. 3HFR Hôpital Fribourgeois, Villars-sur-Glâne, Switzerland.
  4. 4Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Read full textPDFDOICite

Abstract

Introduction

Treatment decisions in older patients with mature B-cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.Methods

We conducted a retrospective real-world study including 172 patients with MBLD between 2016 and 2021, assessing the association of age and comorbidity burden (standardised using the Cumulative Illness Rating Scale for Geriatrics, CIRS-G score) with treatment intensity, toxicity, and clinical outcomes.Results

Treatment intensity decreased significantly with both age (p = 0.003) and CIRS-G score (p < 0.001). However, neither age nor CIRS-G score was associated with an increased rate of treatment-related toxic events. In contrast, older age was associated with worse overall survival and lower response rates (all p < 0.05), whereas CIRS-G score was not significantly associated with these outcomes. Similar associations between age and outcomes were observed in the DLBCL subgroup.Conclusion

In this real-world cohort of patients with MBLD, chronological age was more consistently associated with treatment patterns and clinical outcomes than comorbidity burden as measured by the CIRS-G score. These findings suggest that chronological age alone may not adequately capture the heterogeneity of older patients and support the use of more comprehensive assessments of frailty and functional status to inform treatment decisions.

Related

  1. POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN BRAZIL: CLINICAL-EPIDEMIOLOGICAL FEATURES, HISTOLOGIC PATTERNS, CLINICAL OUTCOMES AND PROGNOSTIC FACTORS
    Karina CACIOLA, Carlos Alberto DA CUNHA, Joaquim GASPARINI DOS SANTOS +9
    Hematology, Transfusion and Cell TherapyPeer-reviewedCC BYFull textOncologyDOAJ
  2. Kidney transplantation outcomes in older adults: the influence of comorbidity burden
    Elsa Vabret, Juliette Piveteau, Mathilde Lassalle +5
    Kidney diseasesPeer-reviewedCC BY-NC 4.0Full textGeneral biologyEpidemiology & public healthHAL
  3. Papillary Morphology, Periampullary Diverticulum, and Comorbidity Burden in Relation to Cannulation Outcomes and Procedural Difficulty in ERCP
    Muhammed Kaya, Hüseyin Köseoğlu, Tolga Düzenli +3
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  4. Unravelling the biological divergence of CD30+ lymphoproliferative disorders with skin involvement: from clinical risk to precision oncology
    Yi Jiang, Yang Wang
    eBioMedicinePeer-reviewedCC BY 4.0General medicineCrossref
  5. Posttransplant lymphoproliferative disorders following hematopoietic stem cell transplantation: a clinicopathological study of a large single-center cohort.
    Jun Lin, Mengyun Zhou, Chang Shen +3
    Annals of hematologyPeer-reviewedCC BYFull textOncologyEurope PMCPMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{nasrinfar2026comorbidity,
  title = {{Age, Comorbidity Burden and Treatment Outcomes in Mature B-Cell Lymphoproliferative Disorders: A Real-World Study.}},
  author = {Kevin Nasrinfar and Harrison Wildhaber and Rudolf Rohr and Gaëlle Rhyner Agocs and Urban Novak and Alessandra Curioni-Fontecedro and Vérène Dougoud-Chauvin},
  journal = {Cancer medicine},
  year = {2026},
  month = nov,
  doi = {10.1002/cam4.72460},
  url = {https://europepmc.org/article/MED/42968459},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Age, Comorbidity Burden and Treatment Outcomes in Mature B-Cell Lymphoproliferative Disorders: A Real-World Study.
AU  - Kevin Nasrinfar
AU  - Harrison Wildhaber
AU  - Rudolf Rohr
AU  - Gaëlle Rhyner Agocs
AU  - Urban Novak
AU  - Alessandra Curioni-Fontecedro
AU  - Vérène Dougoud-Chauvin
PY  - 2026
DA  - 2026/11/01
JO  - Cancer medicine
DO  - 10.1002/cam4.72460
UR  - https://europepmc.org/article/MED/42968459
AB  - Introduction  Treatment decisions in older patients with mature B-cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.Methods  We conducted a retrospective real-world study including 172 patients with MBLD between 2016 and 2021, assessing the association of age and comorbidity burden (standardised using the Cumulative Illness Rating Scale for Geriatrics, CIRS-G score) with treatment intensity, toxicity, and clinical outcomes.Results  Treatment intensity decreased significantly with both age (p = 0.003) and CIRS-G score (p < 0.001). However, neither age nor CIRS-G score was associated with an increased rate of treatment-related toxic events. In contrast, older age was associated with worse overall survival and lower response rates (all p < 0.05), whereas CIRS-G score was not significantly associated with these outcomes. Similar associations between age and outcomes were observed in the DLBCL subgroup.Conclusion  In this real-world cohort of patients with MBLD, chronological age was more consistently associated with treatment patterns and clinical outcomes than comorbidity burden as measured by the CIRS-G score. These findings suggest that chronological age alone may not adequately capture the heterogeneity of older patients and support the use of more comprehensive assessments of frailty and functional status to inform treatment decisions.
SN  - 2045-7634
ER  -